Streetbeat News

DYN

Dyne Therapeutics, Inc.

Industry

Biotechnology

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Open

29.29

Mkt cap

2.9B

Volume

1.2M

High

29.52

P/E Ratio

-7.96

52-wk high

47.45

Low

28.14

Div yield

N/A

52-wk low

8.04

Dyne Therapeutics shares fell after JP Morgan downgraded the stock from Overweight to Neutral and reduced its price target from $43 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 6:38 pm

JP Morgan analyst Tessa Romero has downgraded Dyne Therapeutics from Overweight to Neutral and reduced the price target from $43 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:10 am

Dyne Therapeutics (NYSE:DYN) has seen a 15.97% increase in its short percent of float, now at 10.53%. This indicates a bearish sentiment among investors, although it is below the peer group average of 15.50%.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 8:00 pm

Dyne Therapeutics (NYSE:DYN) has seen an 11.55% increase in its short percent of float, now at 9.08%. This indicates a bearish sentiment among investors, although it is below the peer group average of 15.27%.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 5:15 pm

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Dyne Therapeutics, maintaining a price target of $53.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:36 pm

HC Wainwright & Co. has reiterated its Buy rating for Dyne Therapeutics, maintaining a price target of $55. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:32 am

U.S. stocks fell with the S&P 500 down 2%. SPAR Group shares surged 65% after announcing an acquisition agreement. Sify Technologies shares rose 112% due to a new certification. Conifer Holdings shares increased 83% after selling its insurance agency operations. IO Biotech, Dyne Therapeutics, and Recursion Pharmaceuticals saw significant stock declines.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 6:59 pm

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating for Dyne Therapeutics, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 5:52 pm

Recursion Pharmaceuticals shares fell 11.6% after announcing Phase 2 data for a treatment for Cerebral Cavernous Malformation. Nikola shares also dipped 10.4%. Meanwhile, Sify Technologies surged 103% after achieving a significant certification, and SPAR Group rose 65% following an acquisition agreement.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 5:41 pm

Dyne Therapeutics' stock dropped significantly after releasing new data from its Phase 1/2 DELIVER trial for DYNE-251, a drug for Duchenne muscular dystrophy. Despite showing higher dystrophin expression levels compared to Sarepta's EXONDYS 51, the stock fell by 31.90%.

Portfolio Pulse from Vandana Singh

September 03, 2024 | 4:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.